| 前收盘价格 | 1.46 |
| 收盘价格 | 1.49 |
| 成交量 | 251,705 |
| 平均成交量 (3个月) | 408,828 |
| 市值 | 215,291,168 |
| 价格/销量 (P/S) | 2.58 |
| 股市价格/股市净资产 (P/B) | 7.62 |
| 52周波幅 | |
| 利润日期 | 27 Feb 2025 - 3 Mar 2025 |
| 营业毛利率 | -66.84% |
| 营业利益率 (TTM) | -47.33% |
| 稀释每股收益 (EPS TTM) | -0.370 |
| 季度收入增长率 (YOY) | 34.50% |
| 总债务/股东权益 (D/E MRQ) | 226.08% |
| 流动比率 (MRQ) | 3.40 |
| 营业现金流 (OCF TTM) | -56.84 M |
| 杠杆自由现金流 (LFCF TTM) | -43.44 M |
| 资产报酬率 (ROA TTM) | -22.79% |
| 股东权益报酬率 (ROE TTM) | -331.82% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 混合的 |
| Diagnostics & Research (全球的) | 混合的 | 混合的 | |
| 股票 | Biodesix, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.83 |
|
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 48.62% |
| 机构持股比例 | 42.83% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Wilmington Savings Fund Society, Fsb | 30 Sep 2024 | 6,095,034 |
| Birchview Capital, Lp | 30 Sep 2024 | 5,541,176 |
| Silverarc Capital Management, Llc | 30 Sep 2024 | 3,561,094 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合